10:25 AM EDT, 03/12/2024 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) said Tuesday that new data from two studies evaluating Voxzogo showed that it can lead to height gains in children with achondroplasia and improve their quality of life.

In the phase 2 study with more than seven years of follow up, BioMarin said treatment with Voxzogo resulted in a mean increase in growth of 1.63 cm per year for boys and 1.33 cm per year for girls. In the phase 3 study spanning four years, the mean increase in growth was 1.73 cm per year for boys and 1.46 cm per year for girls, the company said.

The medicine, also known as vosoritide, also showed the potential to impact growth outcomes in children with hypochondroplasia, a genetic skeletal disorder that stunts growth, based on phase 2 trial results, BioMarin said.

The company said the study showed Voxzogo increased annualized growth velocity from 5.12 cm per year during the observation period to 6.93 cm per year during the treatment period. Phase 3 trial is planned for later this year, according to the company.

Price: 85.85, Change: -0.15, Percent Change: -0.18